Preclinical safety and efficacy of lentiviral-mediated gene therapy for leukocyte adhesion deficiency type I

Mesa-Núñez, Cristina; Damián, Carlos; Fernández-García, María; Díez, Begoña; Rao, Gayatri; Schwartz, Jonathan D.; Law, Ken M.; Sevilla, Julián; Rı́o, Paula; Yáñez, Rosa María Pérez; Bueren, Juan A.; Almarza, Elena

doi:10.1016/j.omtm.2022.07.015

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been much debate about inclusion of IL-3 in the cytokine cocktail, with some current HSCGT protocols include IL-3 in TD media, where others exclude the cytokine. 35 , 43 , 44 It was evident from our studies that including IL-3 in addition to the standard SCF, FLT-3, and TPO cytokines increased VCN and IDS enzyme activity when evaluated after short-term CFU and LCs, in agreement with findings from other studies evaluating LV-EFS-ADA TD of CD34 + cells for ADA deficiency. 45 Carbonaro et al.…”

Section: Discussionsupporting

confidence: 91%

Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy

Ellison,

Buckland,

Learmonth

et al. 2024

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy

Ellison,

Buckland,

Learmonth

et al. 2024

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

“…HSCT leads to 75% overall survival [ 101 ]. Preclinical studies in animal models showed feasibility of gene therapy with a viral vector [ 102 , 103 ]. However, initial trials using gRV vector were unsuccessful and terminated early as no corrected cells were detected [ 104 ].…”

Section: Gene Therapy For Other Iei Than Severe Combined Immunodefici...mentioning

confidence: 99%

Advances in gene therapy for inborn errors of immunity

Ott de Bruin,

Lankester,

Staal

2023

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review Provide an overview of the landmark accomplishments and state of the art of gene therapy for inborn errors of immunity (IEI). Recent findings Three decades after the first clinical application of gene therapy for IEI, there is one market authorized product available, while for several others efficacy has been demonstrated or is currently being tested in ongoing clinical trials. Gene editing approaches using programmable nucleases are being explored preclinically and could be beneficial for genes requiring tightly regulated expression, gain-of-function mutations and dominant-negative mutations. Summary Gene therapy by modifying autologous hematopoietic stem cells (HSCs) offers an attractive alternative to allogeneic hematopoietic stem cell transplantation (HSCT), the current standard of care to treat severe IEI. This approach does not require availability of a suitable allogeneic donor and eliminates the risk of graft versus host disease (GvHD). Gene therapy can be attempted by using a viral vector to add a copy of the therapeutic gene (viral gene addition) or by using programmable nucleases (gene editing) to precisely correct mutations, disrupt a gene or introduce an entire copy of a gene at a specific locus. However, gene therapy comes with its own challenges such as safety, therapeutic effectiveness and access. For viral gene addition, a major safety concern is vector-related insertional mutagenesis, although this has been greatly reduced with the introduction of safer vectors. For gene editing, the risk of off-site mutagenesis is a main driver behind the ongoing search for modified nucleases. For both approaches, HSCs have to be manipulated ex vivo, and doing this efficiently without losing stemness remains a challenge, especially for gene editing.

show abstract